NovoCure Analyst Ratings
NovoCure Analyst Ratings
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
NovoCure Analyst Ratings
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
NovoCure Analyst Ratings
NovoCure Analyst Ratings
NovoCure's TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed With Raised Price Target
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
NovoCure Analyst Ratings
Nuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure's Stock
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), CareMax (CMAX) and NovoCure (NVCR)
NovoCure Analyst Ratings
Buy Rating Affirmed for NovoCure Amid Strong Q4 Performance and Promising Pipeline Developments
NovoCure Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for NovoCure (NVCR)
Buy Rating Affirmed for NovoCure Amid Positive Clinical Results and Solid Financial Performance
NovoCure Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for NovoCure (NVCR)